Clinical Trial Update: U.S. Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR [NA]

View source ↗

Summary

The U.S. multicenter feasibility trial of the F2 Filter and Delivery System for embolic protection during TAVR has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Stenosis

Snippet

Sponsor: EnCompass Technologies, Inc. | Conditions: Aortic Stenosis | NA | Status: WITHDRAWN